ErbA: tumor suppressor turned oncogene?
- PMID: 8102105
- DOI: 10.1096/fasebj.7.10.8102105
ErbA: tumor suppressor turned oncogene?
Abstract
Cancer has been commonly linked to aberrant proliferation and a failure of the transformed cells to differentiate. Activated proto-oncogenes are thought to provide continuous proliferation signals that enhance the growth of these cells. Conversely, cellular transformation may also be achieved by the inactivation of genes whose normal function is to constrain cell growth by either suppressing proliferation or inducing differentiation. Such an inactivation could result from dominant-negative mutations, leading to the expression of abnormal proteins that inhibit the function of their normal counterparts. A prototype example is the v-erbA oncogene of the avian erythroblastosis virus (AEV), which antagonizes the transcriptional regulatory function of the chicken c-ErbA/thyroid hormone receptors (c-ErbA/TR) and the structurally related retinoic acid receptors (RARs). The result of this inhibition is a loss of hormone responsiveness and hormone-induced differentiation. Here we have a parallel to the tumor suppressor gene where it is also a loss of function that induces the transformation process. In this way, the normal, hormone-activated c-ErbA/TRs and RARs act as growth suppressors because the resulting differentiated cells irreversibly lose proliferative potential. In this article, the properties of v-ErbA will be discussed in the context of c-ErbA/thyroid hormone and retinoic acid receptor function.
Similar articles
-
Modulation of normal erythroid differentiation by the endogenous thyroid hormone and retinoic acid receptors: a possible target for v-erbA oncogene action.Oncogene. 1992 Feb;7(2):217-27. Oncogene. 1992. PMID: 1347914
-
The v-erbA oncogene requires cooperation with tyrosine kinases to arrest erythroid differentiation induced by ligand-activated endogenous c-erbA and retinoic acid receptor.Oncogene. 1992 Feb;7(2):203-16. Oncogene. 1992. PMID: 1347913
-
V-erbA requires auxiliary proteins for dominant negative activity.Oncogene. 1993 Jan;8(1):55-65. Oncogene. 1993. PMID: 8093812
-
c-erbA: protooncogene or growth suppressor gene?Adv Cancer Res. 1992;59:89-113. doi: 10.1016/s0065-230x(08)60304-8. Adv Cancer Res. 1992. PMID: 1355627 Review. No abstract available.
-
The leukaemia oncogene v-erbA: a dominant negative version of ligand dependent transcription factors that regulates red cell differentiation?Cancer Surv. 1992;14:169-80. Cancer Surv. 1992. PMID: 1358441 Review.
Cited by
-
Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.Future Oncol. 2010 Apr;6(4):587-603. doi: 10.2217/fon.10.15. Future Oncol. 2010. PMID: 20373871 Free PMC article. Review.
-
Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.PLoS One. 2012;7(8):e41660. doi: 10.1371/journal.pone.0041660. Epub 2012 Aug 23. PLoS One. 2012. PMID: 22927913 Free PMC article.
-
Elevated expression of thyroid hormone receptor alpha 2 (c-erb A- alpha 2) in nasopharyngeal carcinoma.Br J Cancer. 2000 Dec;83(12):1674-80. doi: 10.1054/bjoc.2000.1505. Br J Cancer. 2000. PMID: 11104565 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources